AR087053A1 - Uso de un compuesto piperazin-piridinico para la fabricacion de una composicion farmaceutica util para el tratamiento de la tos post-viral, la tos viral o la tos aguda viral - Google Patents
Uso de un compuesto piperazin-piridinico para la fabricacion de una composicion farmaceutica util para el tratamiento de la tos post-viral, la tos viral o la tos aguda viralInfo
- Publication number
- AR087053A1 AR087053A1 ARP120102419A ARP120102419A AR087053A1 AR 087053 A1 AR087053 A1 AR 087053A1 AR P120102419 A ARP120102419 A AR P120102419A AR P120102419 A ARP120102419 A AR P120102419A AR 087053 A1 AR087053 A1 AR 087053A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- linear
- substituted
- branched
- methyl
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 4
- 230000001154 acute effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- -1 piperazin-pyridine compound Chemical class 0.000 abstract 4
- 206010011224 Cough Diseases 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- GEXJFIOPGAASTP-UHFFFAOYSA-N $l^{1}-azanylethane Chemical compound CC[N] GEXJFIOPGAASTP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000004193 piperazinyl group Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- GGIVIDRZYQYSAA-UHFFFAOYSA-N Cl.CC(CC(=O)O)(C)C.CC(CC(=O)O)(C)C Chemical compound Cl.CC(CC(=O)O)(C)C.CC(CC(=O)O)(C)C GGIVIDRZYQYSAA-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- LUYRXEBAUOSYEL-UHFFFAOYSA-N propan-2-yl 2-[4-[[4-[[(2-chloro-6-fluorophenyl)methyl-ethylamino]methyl]phenyl]methyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound FC=1C=CC=C(Cl)C=1CN(CC)CC(C=C1)=CC=C1CN(CC1)CCN1C1=NC=CC=C1C(=O)OC(C)C LUYRXEBAUOSYEL-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003944 tolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un compuesto piperazin-piridínico de fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: n es 0 o un número entero de 1 a 5; Y es alquilo C₁₋₆ lineal o ramificado o cicloalquilo; R¹ es H, halógeno, alquilo C₁₋₆ lineal o ramificado, fenilo, fenilo sustituido, NHR¹ᵃ, SR¹ᵇ u -OR¹ᶜ; R³ es uno o más sustituyentes seleccionados independientemente entre -H, -OH, -CN, halógeno, alquilo C₁₋₆ lineal o ramificado, -haloalquilo C₁₋₆ lineal o ramificado, -alcoxi C₁₋₆ lineal o ramificado, -alcoxi C₁₋₆ lineal o ramificado, -O(CH₂)ˣOR¹ᵈ, -C(O)R¹ᵉ, -C(O)OR¹ᶠ, -fenilo, -(CH₂)ˣ-fenilo, -(CH₂)ˣ-fenilo sustituido, -feniloxi, -feniloxi sustituido, -(CH₂)ˣ-feniloxi, -(CH₂)ˣ-piperazinilo, -(CH₂)ˣ-piperazinilo sustituido, -(CH₂)ˣ-N-piperazinilo sustituido, -(CH₂)ˣNRC(O)-fenilo, -(CH₂)ˣNRC(O)fenilo sustituido, -O-(CH₂)ˣ-fenilo, -O-(CH₂)ˣ-fenilo sustituido, -O(CH₂)ˣ-1,4-benzodioxinilo, -O(CH₂)ˣ-naftalenilo, -O(CH₂)ˣ-tetrazolilo, -S-fenilo, -S(CH₂)ˣ-fenilo, -SO₂R¹ᵍ, -SO₂N(R¹ᵍ)₂, -(CH₂)ˣ-N(R¹ʰ)-(CH₂)ˣR¹ⁱ; donde: R¹ᵃ, R¹ᵇ o R¹ᶜ, como se ha definido anteriormente en R¹, es fenilo o fenilo sustituido; R, R¹ᵈ, R¹ᵉ, R¹ᶠ, R¹ᵍ o R¹ʰ, como se ha definido en R³, es H o alquilo C₁₋₆ lineal o ramificado; R¹ⁱ es fenilo, fenilo sustituido, furanilo, furanilo sustituido, tienilo o tienilo sustituido; x, como se ha definido para los sustituyentes definidos anteriormente, es 0 o un número entero de 1 a 5; donde: cada sustituyente como se ha definido en R³ anterior está opcionalmente sustituido adicionalmente con uno o más de los siguientes sustituyentes seleccionados entre: -H, -OH, -CN, -NO₂, -halógeno, -(CH₂)ʸ-OH, -O(CH₂)ʸCN, -OC(O)OH, -OC(O)R¹ʲ, -C(O)OR¹ᵏ, -O(CH₂)ʸOR¹ˡ, -alquilo C₁₋₆ lineal o ramificado, -haloalquilo C₁₋₆ lineal o ramificado, -alcoxi C₁₋₆ lineal o ramificado, -NR¹ᵐR¹ⁿ, SO₂R¹ᵒ, S(CH₂)ʸR¹ᵖ, NR¹qC(O)R¹ʳ, arilo o heteroarilo; donde: y, como se ha definido para las variables anteriores, es 0 o un número entero de 1 a 5; R¹ʲ, R¹ᵏ, R¹ˡ, R¹ᵐ, R¹ⁿ, R¹ᵒ, R¹ᵖ, R¹q o R¹ʳ es H, alquilo C₁₋₆ lineal o ramificado, fenilo, fenilo sustituido, piridinilo o piridinilo sustituido, -C(O)-fenilo, -C(O)-fenilo sustituido o (CH₂)ˣ-2-oxo-1-pirrolidinilo o (CH₂)ˣ-2-oxo-N-pirrolidinilo; o donde: x es 0 o un número entero de 1 a 5; cada sustituyente fenilo o fenilo sustituido como se ha definido en R¹ʲ, R¹ᵏ, R¹ˡ, R¹ᵐ, R¹ⁿ, R¹ᵒ, R¹ᵖ, R¹q o R¹ʳ anterior está opcionalmente sustituido adicionalmente con uno o más de los siguientes sustituyentes seleccionados entre: -H, -OH, -CN, -NO₂, -halógeno, -(CH₂)ʸ-OH, -OC(O)OH, -OC(O)R¹ˢ, -C(O)OR¹ᵗ, -SO₂N(R¹ᵘ)₂-, alquilo C₁₋₆ lineal o ramificado, -haloalquilo C₁₋₆ lineal o ramificado, -alcoxi C₁₋₆ lineal o ramificado; donde: R¹ˢ, R¹ᵗ, o R¹ᵘ como se ha definido anteriormente es H, alquilo C₁₋₆ lineal o ramificado, fenilo o fenilo sustituido; para la fabricación de una composición farmacéutica útil para el tratamiento de la tos post-viral, la tos viral o la tos aguda viral. Reivindicación 10: El uso de la reivindicación 1, caracterizado porque el compuesto de fórmula (1) se selecciona entre: 2-{4-[(4-{[[(2-cloro-6-fluorofenil)metil](etil)amino]metil}fenil)metil]-1-piperazinil}-3-piridincarboxilato de 1-metiletilo; di-maleato de 1-[(4-{[[(2-cloro-6-fluorofenil)metil](etil)amonio]metil}-fenil)metil)-4-(3-{[(1-metiletil)oxi]carbonil}-2-piridinil)piperazin-1-ilo; dihidrocloruro de 2-{4-[(4-{[[(2-cloro-6-fluorofenil)metil](etil)amino]metil}fenil)metil]-1-piperazinil}-3-piridincarboxilato de 1-metiletilo; hidrocloruro de bis(3,3-dimetilbutanoato) de bencen-1,4-diilbis[metanodiil-(etilimino)(3R)-3,1-pirrolidinediil-2,3-piridinadiil metanodillo]; y 2,2-{bencen-1,4-diilbis-[metanodiil(etilimino)(3S)-3,1-pirrolidinadiil]}di(3-piridincarboxilato) de bis(1-metiletilo).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505075P | 2011-07-06 | 2011-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087053A1 true AR087053A1 (es) | 2014-02-12 |
Family
ID=47437403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102419A AR087053A1 (es) | 2011-07-06 | 2012-07-04 | Uso de un compuesto piperazin-piridinico para la fabricacion de una composicion farmaceutica util para el tratamiento de la tos post-viral, la tos viral o la tos aguda viral |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20140121213A1 (es) |
| EP (1) | EP2729149A4 (es) |
| JP (1) | JP2014518281A (es) |
| KR (1) | KR20140059774A (es) |
| CN (1) | CN103764148A (es) |
| AR (1) | AR087053A1 (es) |
| AU (1) | AU2012279091A1 (es) |
| BR (1) | BR112014000259A2 (es) |
| CA (1) | CA2840394A1 (es) |
| CL (1) | CL2014000020A1 (es) |
| CO (1) | CO6821963A2 (es) |
| CR (1) | CR20140002A (es) |
| DO (1) | DOP2014000001A (es) |
| EA (1) | EA201490210A1 (es) |
| MA (1) | MA35336B1 (es) |
| MX (1) | MX2014000112A (es) |
| PE (1) | PE20141385A1 (es) |
| PH (1) | PH12014500006A1 (es) |
| TW (1) | TW201302707A (es) |
| WO (1) | WO2013006596A1 (es) |
| ZA (1) | ZA201309533B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9597330B2 (en) | 2013-03-14 | 2017-03-21 | Daiichi Sankyo Company, Limited | Drugs for treating respiratory diseases |
| US10668067B2 (en) | 2016-07-20 | 2020-06-02 | Amgen Inc. | Pyridine sulfonamides |
| WO2020120673A1 (en) * | 2018-12-13 | 2020-06-18 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
| CN109796402A (zh) * | 2018-12-28 | 2019-05-24 | 京博农化科技有限公司 | 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法 |
| WO2023049364A1 (en) | 2021-09-24 | 2023-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
-
2012
- 2012-07-03 JP JP2014519247A patent/JP2014518281A/ja active Pending
- 2012-07-03 EA EA201490210A patent/EA201490210A1/ru unknown
- 2012-07-03 WO PCT/US2012/045350 patent/WO2013006596A1/en not_active Ceased
- 2012-07-03 EP EP12806889.7A patent/EP2729149A4/en not_active Withdrawn
- 2012-07-03 US US14/128,704 patent/US20140121213A1/en not_active Abandoned
- 2012-07-03 CN CN201280041598.8A patent/CN103764148A/zh active Pending
- 2012-07-03 KR KR1020147002808A patent/KR20140059774A/ko not_active Withdrawn
- 2012-07-03 PE PE2014000011A patent/PE20141385A1/es not_active Application Discontinuation
- 2012-07-03 AU AU2012279091A patent/AU2012279091A1/en not_active Abandoned
- 2012-07-03 BR BR112014000259A patent/BR112014000259A2/pt not_active IP Right Cessation
- 2012-07-03 CA CA2840394A patent/CA2840394A1/en not_active Abandoned
- 2012-07-03 PH PH1/2014/500006A patent/PH12014500006A1/en unknown
- 2012-07-03 MX MX2014000112A patent/MX2014000112A/es unknown
- 2012-07-04 TW TW101124063A patent/TW201302707A/zh unknown
- 2012-07-04 AR ARP120102419A patent/AR087053A1/es unknown
-
2013
- 2013-12-17 CO CO13294535A patent/CO6821963A2/es not_active Application Discontinuation
- 2013-12-18 ZA ZA2013/09533A patent/ZA201309533B/en unknown
-
2014
- 2014-01-02 DO DO2014000001A patent/DOP2014000001A/es unknown
- 2014-01-06 CR CR20140002A patent/CR20140002A/es unknown
- 2014-01-06 CL CL2014000020A patent/CL2014000020A1/es unknown
- 2014-02-05 MA MA36731A patent/MA35336B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500006A1 (en) | 2014-02-10 |
| CO6821963A2 (es) | 2013-12-31 |
| CL2014000020A1 (es) | 2014-08-01 |
| CR20140002A (es) | 2014-03-05 |
| CA2840394A1 (en) | 2013-01-10 |
| DOP2014000001A (es) | 2014-04-30 |
| PE20141385A1 (es) | 2014-10-29 |
| MX2014000112A (es) | 2014-01-31 |
| EA201490210A1 (ru) | 2014-05-30 |
| EP2729149A4 (en) | 2015-01-07 |
| TW201302707A (zh) | 2013-01-16 |
| KR20140059774A (ko) | 2014-05-16 |
| CN103764148A (zh) | 2014-04-30 |
| EP2729149A1 (en) | 2014-05-14 |
| MA35336B1 (fr) | 2014-08-01 |
| US20140121213A1 (en) | 2014-05-01 |
| WO2013006596A1 (en) | 2013-01-10 |
| ZA201309533B (en) | 2014-08-27 |
| AU2012279091A1 (en) | 2014-01-16 |
| BR112014000259A2 (pt) | 2017-02-14 |
| JP2014518281A (ja) | 2014-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087053A1 (es) | Uso de un compuesto piperazin-piridinico para la fabricacion de una composicion farmaceutica util para el tratamiento de la tos post-viral, la tos viral o la tos aguda viral | |
| NZ601126A (en) | Voltage-gated sodium channel blockers | |
| NZ622769A (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
| CY1118909T1 (el) | Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| SI3057943T1 (en) | Pyrimidine FGFR4 Inhibitors | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| MX2012002011A (es) | Composicion farmaceutica que contiene derivado de quinolina. | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| JP2017519781A5 (es) | ||
| PE20121509A1 (es) | Compuestos de triazolopiridinas como inhibidores de quinasa mps-1 | |
| RU2014122033A (ru) | Соединения с нематоцидной активностью | |
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| RU2011146363A (ru) | Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета | |
| AR046061A1 (es) | Derivados de acilhidrazona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |